# Clinacin 150 mg Tablets for Dogs

Authorised

- Clindamycin hydrochloride

## Product identification

**Medicine name:**
Clinacin 150 mg Tablets for Dogs
CLINDASEPTIN 150 MG COMPRIMES

**Active substance:**
Clindamycin hydrochloride

**Target species:**
Dog

**Route of administration:**
Oral use

## Product details

**Active substance and strength:**
Clindamycin hydrochloride
162.85 milligram(s) / 1.00 Tablet

**Pharmaceutical form:**
Tablet

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QJ01FF01

**Legal status of supply:**
Veterinary medicinal product subject to veterinary prescription

**Authorisation status:**
Valid

**Authorised in:**
France

**Package description:**
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 10 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 16 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 20 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 30 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 50 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 80 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 100 tablets.

## Additional information

**Entitlement type:**
Marketing Authorisation

**Legal basis of product authorisation:**
Well-established use application (Article 13a of Directive No 2001/82/EC)

**Marketing authorisation holder:**
Chanelle Pharmaceuticals Manufacturing Limited

**Marketing authorisation date:**

23/08/2002

**Manufacturing sites for batch release:**
Chanelle Pharmaceuticals Manufacturing Limited

**Responsible authority:**
French Agency For Food, Environmental And Occupational Health & Safety

**Authorisation number:**
FR/V/2145706 3/2002

**Date of authorisation status change:**
23/08/2007

**Reference member state:**
Ireland

**Procedure number:**
IE/V/0112/003

**Concerned member states:**
Austria Denmark Finland France Germany Greece Portugal Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download